Trial reportMedical science monitor : international medical journal of experimental and clinical research2025
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Clinical and Transcriptomic Profiles Associated with Vitamin D to Enhance Disease-Free Survival in Cervical Cancer Recurrence Using the CatBoost Algorithm.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Cervical cancer is the fourth most common cancer among women. The case fatality rate of advanced-stage cervical cancer was approximately 50% in 2020 worldwide. A new approach to finding a better treatment outcome for advanced-stage cervical cancer is needed. Research findings showed that cholecalciferol may benefit cancer cell control. This study aimed to understand the impact of cholecalciferol supplementation on advanced-stage cervical cancer treatment by radiotherapy. MATERIAL AND METHODS A randomized controlled trial with a pretest-posttest control group design was conducted between 2021 and 2023 at Dr. Hasan Sadikin Hospital, Bandung, Indonesia. Eligible consecutive patients were recruited and randomly assigned to either the Treatment or Control group using a simple randomization method. The Treatment group received 10 000 IU of cholecalciferol daily for 7 weeks during radiotherapy and for 12 weeks after treatment, while the Control group received a placebo in addition to the same radiotherapy protocol. Clinical outcomes were assessed 3 months after treatment completion. RESULTS We recruited 123 subjects in this study. The complete response rate was 82.61% in the Treatment group and 64.8% in the Control group. The Treatment group had a higher average serum cholecalciferol level after completion of the protocol. CONCLUSIONS Supplementation with 10 000 IU of cholecalciferol among advanced-stage cervical cancer patients undergoing radiotherapy treatment resulted in improved therapeutic response and maintaining serum cholecalciferol levels, which may further benefit cancer-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.